These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24385293)

  • 1. Age-related decline in dopamine transporter in human brain using PET with a new radioligand [¹⁸F]FE-PE2I.
    Shingai Y; Tateno A; Arakawa R; Sakayori T; Kim W; Suzuki H; Okubo Y
    Ann Nucl Med; 2014 Apr; 28(3):220-6. PubMed ID: 24385293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
    Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
    J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
    Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
    J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.
    Sasaki T; Ito H; Kimura Y; Arakawa R; Takano H; Seki C; Kodaka F; Fujie S; Takahata K; Nogami T; Suzuki M; Fujiwara H; Takahashi H; Nakao R; Fukumura T; Varrone A; Halldin C; Nishikawa T; Suhara T
    J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal DAT changes measured with [
    Kerstens VS; Fazio P; Sundgren M; Brumberg J; Halldin C; Svenningsson P; Varrone A
    Neuroimage Clin; 2023; 37():103347. PubMed ID: 36822016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproducibility of PET measurement for presynaptic dopaminergic functions using L-[β-(11)C]DOPA and [(18)F]FE-PE2I in humans.
    Suzuki M; Ito H; Kodaka F; Takano H; Kimura Y; Fujiwara H; Sasaki T; Takahata K; Nogami T; Nagashima T; Nengaki N; Kawamura K; Zhang MR; Varrone A; Halldin C; Okubo Y; Suhara T
    Nucl Med Commun; 2014 Mar; 35(3):231-7. PubMed ID: 24468851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand.
    Varrone A; Steiger C; Schou M; Takano A; Finnema SJ; Guilloteau D; Gulyás B; Halldin C
    Synapse; 2009 Oct; 63(10):871-80. PubMed ID: 19562698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification and discriminative power of
    Delva A; Van Weehaeghe D; van Aalst J; Ceccarini J; Koole M; Baete K; Nuyts J; Vandenberghe W; Van Laere K
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1913-1926. PubMed ID: 31776633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models.
    Seki C; Ito H; Ichimiya T; Arakawa R; Ikoma Y; Shidahara M; Maeda J; Takano A; Takahashi H; Kimura Y; Suzuki K; Kanno I; Suhara T
    Ann Nucl Med; 2010 May; 24(4):249-60. PubMed ID: 20364374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of semi-quantitative method for quantification of dopamine transporter in human PET study with ¹⁸F-FE-PE2I.
    Ikoma Y; Sasaki T; Kimura Y; Seki C; Okubo Y; Suhara T; Ito H
    Ann Nucl Med; 2015 Oct; 29(8):697-708. PubMed ID: 26134215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study.
    Jucaite A; Odano I; Olsson H; Pauli S; Halldin C; Farde L
    Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):657-68. PubMed ID: 16514530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
    Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
    J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high-resolution PET study.
    Leroy C; Karila L; Martinot JL; Lukasiewicz M; Duchesnay E; Comtat C; Dollé F; Benyamina A; Artiges E; Ribeiro MJ; Reynaud M; Trichard C
    Addict Biol; 2012 Nov; 17(6):981-90. PubMed ID: 21812871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dopamine transporter binding in the nucleus accumbens in geriatric patients with severe depression.
    Moriya H; Tiger M; Tateno A; Sakayori T; Masuoka T; Kim W; Arakawa R; Okubo Y
    Psychiatry Clin Neurosci; 2020 Aug; 74(8):424-430. PubMed ID: 32363761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter.
    Arakawa R; Ichimiya T; Ito H; Takano A; Okumura M; Takahashi H; Takano H; Yasuno F; Kato M; Okubo Y; Suhara T
    J Psychiatr Res; 2009 Oct; 43(15):1219-23. PubMed ID: 19457493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VNTR polymorphism in the SLC6A3 gene does not influence dopamine transporter availability measured by [18F]FE-PE2I PET or [123I]FP-Cit SPECT.
    Jakobson Mo S; Axelsson J; Stiernman LJ; Larsson A; Af Bjerkén S; Bäckström D; Kellgren TG; Varrone A; Riklund K
    Nucl Med Commun; 2022 Mar; 43(3):247-255. PubMed ID: 34908018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of 11C-PE2I binding to the neuronal dopamine transporter in humans with the high-spatial-resolution PET scanner HRRT.
    Leroy C; Comtat C; Trébossen R; Syrota A; Martinot JL; Ribeiro MJ
    J Nucl Med; 2007 Apr; 48(4):538-46. PubMed ID: 17401089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional analysis of age-related decline in dopamine transporters and dopamine D2-like receptors in human striatum.
    Ishibashi K; Ishii K; Oda K; Kawasaki K; Mizusawa H; Ishiwata K
    Synapse; 2009 Apr; 63(4):282-90. PubMed ID: 19116949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliability of dopamine transporter PET measurements with [
    Kerstens VS; Fazio P; Sundgren M; Matheson GJ; Franzén E; Halldin C; Cervenka S; Svenningsson P; Varrone A
    EJNMMI Res; 2020 Aug; 10(1):95. PubMed ID: 32797307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility.
    Hirvonen J; Johansson J; Teräs M; Oikonen V; Lumme V; Virsu P; Roivainen A; Någren K; Halldin C; Farde L; Hietala J
    J Cereb Blood Flow Metab; 2008 May; 28(5):1059-69. PubMed ID: 18183028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.